Aurobindo Pharma Ltd. - Research Center
524804 AUROPHARMA Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | Mar ' 16 | |
|---|---|---|---|---|---|
| Sales | 13,266.48 | 12,257.89 | 10,303.15 | 9,781.21 | 9,322.76 |
| Operating profit | 2,685.75 | 2,398.97 | 2,670.01 | 2,373.95 | 2,287.74 |
| Interest | 95.58 | 130.92 | 52.89 | 45.16 | 65.27 |
| Gross profit | 2,848.18 | 2,377.65 | 2,697.77 | 2,464.74 | 2,410.84 |
| EPS (Rs) | 31.96 | 26.11 | 30.94 | 29.13 | 27.80 |
Annual
results in details
| Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | Mar ' 16 | |
|---|---|---|---|---|---|
| Other income | 258.01 | 109.60 | 80.65 | 135.95 | 188.37 |
| Stock adjustment | -229.53 | -289.80 | -334.18 | 31.32 | -141.59 |
| Raw material | 6,747.55 | 6,455.30 | 4,893.27 | 4,604.19 | 4,425.80 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 1,561.47 | 1,362.77 | 1,131.64 | 927.30 | 807.05 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 2,501.24 | 2,330.65 | 1,942.41 | 1,844.45 | 1,943.76 |
| Provisions made | - | - | - | - | - |
| Depreciation | 470.48 | 413.03 | 354.83 | 286.17 | 263.00 |
| Taxation | 504.96 | 434.89 | 530.17 | 471.81 | 521.14 |
| Net profit / loss | 1,872.74 | 1,529.73 | 1,812.77 | 1,706.76 | 1,626.70 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 58.59 | 58.59 | 58.59 | 58.59 | 58.52 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 20.24 | 19.57 | 25.91 | 24.27 | 24.54 |
| GPM (%) | 21.06 | 19.23 | 25.98 | 24.85 | 25.35 |
| NPM (%) | 13.85 | 12.37 | 17.46 | 17.21 | 17.10 |
© 2021 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis